#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Bacterial Membrane Vesicles , which respond to the extracellular vesicles ( EVs ) definition criteria , are membrane structures , produced by Gram-negative , Gram-positive and Mycobacteria microorganisms during their growth .
2-1	16-25	Bacterial	substance|abstract[4]	new|new[4]	coref|coref	2-18[10_4]|5-35
2-2	26-34	Membrane	object|abstract[4]	new|new[4]	coref	2-18
2-3	35-43	Vesicles	abstract[4]	new[4]	_	_
2-4	44-45	,	_	_	_	_
2-5	46-51	which	_	_	_	_
2-6	52-59	respond	_	_	_	_
2-7	60-62	to	_	_	_	_
2-8	63-66	the	abstract[5]	new[5]	appos	2-12[0_5]
2-9	67-80	extracellular	abstract[5]	new[5]	_	_
2-10	81-89	vesicles	abstract[5]	new[5]	_	_
2-11	90-91	(	_	_	_	_
2-12	92-95	EVs	abstract	giv	coref	4-6
2-13	96-97	)	_	_	_	_
2-14	98-108	definition	abstract|abstract[8]	new|new[8]	_	_
2-15	109-117	criteria	abstract[8]	new[8]	_	_
2-16	118-119	,	_	_	_	_
2-17	120-123	are	_	_	_	_
2-18	124-132	membrane	object|abstract[10]	giv|giv[10]	coref	6-9[52_0]
2-19	133-143	structures	abstract[10]	giv[10]	_	_
2-20	144-145	,	_	_	_	_
2-21	146-154	produced	_	_	_	_
2-22	155-157	by	_	_	_	_
2-23	158-171	Gram-negative	substance	new	coref	15-53[187_0]
2-24	172-173	,	_	_	_	_
2-25	174-187	Gram-positive	animal[12]	new[12]	ana	2-30[0_12]
2-26	188-191	and	animal[12]	new[12]	_	_
2-27	192-204	Mycobacteria	animal[12]	new[12]	_	_
2-28	205-219	microorganisms	animal[12]	new[12]	_	_
2-29	220-226	during	_	_	_	_
2-30	227-232	their	animal|abstract[14]	giv|new[14]	coref	8-33[0_14]
2-31	233-239	growth	abstract[14]	new[14]	_	_
2-32	240-241	.	_	_	_	_

#Text=These elements are spherical in shape , with an average size in the range from 20 to 500 nm and deliver several components , such as proteins , nucleic acids , and phospholipids .
3-1	242-247	These	object[15]	new[15]	_	_
3-2	248-256	elements	object[15]	new[15]	_	_
3-3	257-260	are	_	_	_	_
3-4	261-270	spherical	_	_	_	_
3-5	271-273	in	_	_	_	_
3-6	274-279	shape	abstract	new	_	_
3-7	280-281	,	_	_	_	_
3-8	282-286	with	_	_	_	_
3-9	287-289	an	abstract[17]	new[17]	_	_
3-10	290-297	average	abstract[17]	new[17]	_	_
3-11	298-302	size	abstract[17]	new[17]	_	_
3-12	303-305	in	abstract[17]	new[17]	_	_
3-13	306-309	the	abstract[17]|abstract[18]	new[17]|new[18]	ana	4-1[0_18]
3-14	310-315	range	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-15	316-320	from	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-16	321-323	20	abstract[17]|abstract[18]|quantity	new[17]|new[18]|new	_	_
3-17	324-326	to	_	_	_	_
3-18	327-330	500	quantity[20]	new[20]	_	_
3-19	331-333	nm	quantity[20]	new[20]	_	_
3-20	334-337	and	_	_	_	_
3-21	338-345	deliver	_	_	_	_
3-22	346-353	several	abstract[21]	new[21]	_	_
3-23	354-364	components	abstract[21]	new[21]	_	_
3-24	365-366	,	abstract[21]	new[21]	_	_
3-25	367-371	such	abstract[21]	new[21]	_	_
3-26	372-374	as	abstract[21]	new[21]	_	_
3-27	375-383	proteins	abstract[21]|substance	new[21]|new	_	_
3-28	384-385	,	abstract[21]	new[21]	_	_
3-29	386-393	nucleic	abstract[21]|substance[23]	new[21]|new[23]	_	_
3-30	394-399	acids	abstract[21]|substance[23]	new[21]|new[23]	_	_
3-31	400-401	,	abstract[21]	new[21]	_	_
3-32	402-405	and	abstract[21]	new[21]	_	_
3-33	406-419	phospholipids	abstract[21]|substance	new[21]|new	_	_
3-34	420-421	.	_	_	_	_

#Text=It has been reported that EVs are involved in a number of physiological and pathological mechanisms , including biofilm formation , inter-cellular cross-talk , as well as bacteria – host and bacterium – phage interactions .
4-1	422-424	It	abstract	giv	_	_
4-2	425-428	has	_	_	_	_
4-3	429-433	been	_	_	_	_
4-4	434-442	reported	_	_	_	_
4-5	443-447	that	_	_	_	_
4-6	448-451	EVs	abstract	giv	coref	5-10
4-7	452-455	are	_	_	_	_
4-8	456-464	involved	_	_	_	_
4-9	465-467	in	_	_	_	_
4-10	468-469	a	abstract[27]	new[27]	_	_
4-11	470-476	number	abstract[27]	new[27]	_	_
4-12	477-479	of	abstract[27]	new[27]	_	_
4-13	480-493	physiological	abstract[27]	new[27]	_	_
4-14	494-497	and	abstract[27]	new[27]	_	_
4-15	498-510	pathological	abstract[27]	new[27]	_	_
4-16	511-521	mechanisms	abstract[27]	new[27]	_	_
4-17	522-523	,	abstract[27]	new[27]	_	_
4-18	524-533	including	abstract[27]	new[27]	_	_
4-19	534-541	biofilm	abstract[27]|object|abstract[29]	new[27]|new|new[29]	coref	11-26
4-20	542-551	formation	abstract[27]|abstract[29]	new[27]|new[29]	_	_
4-21	552-553	,	abstract[27]	new[27]	_	_
4-22	554-568	inter-cellular	abstract[27]|abstract[30]	new[27]|new[30]	_	_
4-23	569-579	cross-talk	abstract[27]|abstract[30]	new[27]|new[30]	_	_
4-24	580-581	,	_	_	_	_
4-25	582-584	as	_	_	_	_
4-26	585-589	well	_	_	_	_
4-27	590-592	as	_	_	_	_
4-28	593-601	bacteria	animal	new	coref	6-24[55_0]
4-29	602-603	–	_	_	_	_
4-30	604-608	host	person	new	_	_
4-31	609-612	and	_	_	_	_
4-32	613-622	bacterium	animal	new	coref	15-70
4-33	623-624	–	_	_	_	_
4-34	625-630	phage	object|abstract[35]	new|new[35]	_	_
4-35	631-643	interactions	abstract[35]	new[35]	_	_
4-36	644-645	.	_	_	_	_

#Text=Many studies support the hypothesis that the generation of EVs is a controlled and regulated process , although Turnbull et al. demonstrated that the EVs ’ biogenesis is associated with a rearrangement of the bacterial membranes , derived from lysed cells , which incorporate soluble molecules .
5-1	646-650	Many	abstract[36]	new[36]	_	_
5-2	651-658	studies	abstract[36]	new[36]	_	_
5-3	659-666	support	_	_	_	_
5-4	667-670	the	abstract[37]	new[37]	_	_
5-5	671-681	hypothesis	abstract[37]	new[37]	_	_
5-6	682-686	that	abstract[37]	new[37]	_	_
5-7	687-690	the	abstract[37]|event[38]	new[37]|new[38]	coref	5-12[40_38]
5-8	691-701	generation	abstract[37]|event[38]	new[37]|new[38]	_	_
5-9	702-704	of	abstract[37]|event[38]	new[37]|new[38]	_	_
5-10	705-708	EVs	abstract[37]|event[38]|object	new[37]|new[38]|giv	coref	6-6
5-11	709-711	is	abstract[37]	new[37]	_	_
5-12	712-713	a	abstract[37]|event[40]	new[37]|giv[40]	coref	9-28[88_40]
5-13	714-724	controlled	abstract[37]|event[40]	new[37]|giv[40]	_	_
5-14	725-728	and	abstract[37]|event[40]	new[37]|giv[40]	_	_
5-15	729-738	regulated	abstract[37]|event[40]	new[37]|giv[40]	_	_
5-16	739-746	process	abstract[37]|event[40]	new[37]|giv[40]	_	_
5-17	747-748	,	_	_	_	_
5-18	749-757	although	_	_	_	_
5-19	758-766	Turnbull	person	new	_	_
5-20	767-769	et	_	_	_	_
5-21	770-773	al.	_	_	_	_
5-22	774-786	demonstrated	_	_	_	_
5-23	787-791	that	_	_	_	_
5-24	792-795	the	abstract[43]	new[43]	ana	6-1[0_43]
5-25	796-799	EVs	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-26	800-801	’	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-27	802-812	biogenesis	abstract[43]	new[43]	_	_
5-28	813-815	is	_	_	_	_
5-29	816-826	associated	_	_	_	_
5-30	827-831	with	_	_	_	_
5-31	832-833	a	event[44]	new[44]	_	_
5-32	834-847	rearrangement	event[44]	new[44]	_	_
5-33	848-850	of	event[44]	new[44]	_	_
5-34	851-854	the	event[44]|object[46]	new[44]|new[46]	_	_
5-35	855-864	bacterial	event[44]|substance|object[46]	new[44]|giv|new[46]	coref	8-23
5-36	865-874	membranes	event[44]|object[46]	new[44]|new[46]	_	_
5-37	875-876	,	_	_	_	_
5-38	877-884	derived	_	_	_	_
5-39	885-889	from	_	_	_	_
5-40	890-895	lysed	object[47]	new[47]	coref	6-13[53_47]
5-41	896-901	cells	object[47]	new[47]	_	_
5-42	902-903	,	_	_	_	_
5-43	904-909	which	_	_	_	_
5-44	910-921	incorporate	_	_	_	_
5-45	922-929	soluble	substance[48]	new[48]	_	_
5-46	930-939	molecules	substance[48]	new[48]	_	_
5-47	940-941	.	_	_	_	_

#Text=It is also known that EVs fuse with the outer membrane of Gram-negative cells , while they are not able to interact with Gram-positive bacteria .
6-1	942-944	It	abstract	giv	_	_
6-2	945-947	is	_	_	_	_
6-3	948-952	also	_	_	_	_
6-4	953-958	known	_	_	_	_
6-5	959-963	that	_	_	_	_
6-6	964-967	EVs	abstract|abstract[51]	giv|new[51]	ana|coref	7-1[0_51]|7-5
6-7	968-972	fuse	abstract[51]	new[51]	_	_
6-8	973-977	with	abstract[51]	new[51]	_	_
6-9	978-981	the	abstract[51]|object[52]	new[51]|giv[52]	_	_
6-10	982-987	outer	abstract[51]|object[52]	new[51]|giv[52]	_	_
6-11	988-996	membrane	abstract[51]|object[52]	new[51]|giv[52]	_	_
6-12	997-999	of	abstract[51]|object[52]	new[51]|giv[52]	_	_
6-13	1000-1013	Gram-negative	abstract[51]|object[52]|object[53]	new[51]|giv[52]|giv[53]	ana	6-17[0_53]
6-14	1014-1019	cells	abstract[51]|object[52]|object[53]	new[51]|giv[52]|giv[53]	_	_
6-15	1020-1021	,	_	_	_	_
6-16	1022-1027	while	_	_	_	_
6-17	1028-1032	they	object	giv	ana	7-18
6-18	1033-1036	are	_	_	_	_
6-19	1037-1040	not	_	_	_	_
6-20	1041-1045	able	_	_	_	_
6-21	1046-1048	to	_	_	_	_
6-22	1049-1057	interact	_	_	_	_
6-23	1058-1062	with	_	_	_	_
6-24	1063-1076	Gram-positive	animal[55]	giv[55]	_	_
6-25	1077-1085	bacteria	animal[55]	giv[55]	_	_
6-26	1086-1087	.	_	_	_	_

#Text=It was demonstrated that EVs stemming from Pseudomonas aeruginosa are able to interact with Shigella flexneri pouring their content into the periplasm of eukaryotic cells ; conversely , EVs derived from P. aeruginosa adhere to the cell wall of Staphylococcus aureus .
7-1	1088-1090	It	abstract	giv	_	_
7-2	1091-1094	was	_	_	_	_
7-3	1095-1107	demonstrated	_	_	_	_
7-4	1108-1112	that	_	_	_	_
7-5	1113-1116	EVs	abstract	giv	coref	7-27[64_0]
7-6	1117-1125	stemming	_	_	_	_
7-7	1126-1130	from	_	_	_	_
7-8	1131-1142	Pseudomonas	place	new	_	_
7-9	1143-1153	aeruginosa	_	_	_	_
7-10	1154-1157	are	_	_	_	_
7-11	1158-1162	able	_	_	_	_
7-12	1163-1165	to	_	_	_	_
7-13	1166-1174	interact	_	_	_	_
7-14	1175-1179	with	_	_	_	_
7-15	1180-1188	Shigella	person	new	_	_
7-16	1189-1197	flexneri	_	_	_	_
7-17	1198-1205	pouring	_	_	_	_
7-18	1206-1211	their	object|abstract[61]	giv|new[61]	coref|coref	7-24[63_0]|8-5[0_61]
7-19	1212-1219	content	abstract[61]	new[61]	_	_
7-20	1220-1224	into	_	_	_	_
7-21	1225-1228	the	place[62]	new[62]	_	_
7-22	1229-1238	periplasm	place[62]	new[62]	_	_
7-23	1239-1241	of	place[62]	new[62]	_	_
7-24	1242-1252	eukaryotic	place[62]|object[63]	new[62]|giv[63]	coref	9-55[98_63]
7-25	1253-1258	cells	place[62]|object[63]	new[62]|giv[63]	_	_
7-26	1259-1260	;	_	_	_	_
7-27	1261-1271	conversely	abstract[64]	giv[64]	coref	8-2[0_64]
7-28	1272-1273	,	abstract[64]	giv[64]	_	_
7-29	1274-1277	EVs	abstract[64]	giv[64]	_	_
7-30	1278-1285	derived	_	_	_	_
7-31	1286-1290	from	_	_	_	_
7-32	1291-1293	P.	_	_	_	_
7-33	1294-1304	aeruginosa	_	_	_	_
7-34	1305-1311	adhere	_	_	_	_
7-35	1312-1314	to	_	_	_	_
7-36	1315-1318	the	place[66]	new[66]	_	_
7-37	1319-1323	cell	place|place[66]	new|new[66]	_	_
7-38	1324-1328	wall	place[66]	new[66]	_	_
7-39	1329-1331	of	place[66]	new[66]	_	_
7-40	1332-1346	Staphylococcus	place[66]	new[66]	_	_
7-41	1347-1353	aureus	place[66]	new[66]	_	_
7-42	1354-1355	.	_	_	_	_

#Text=The EVs composition and content are strictly dependent on the environmental conditions where they are generated , as well as on the bacterial species from which they are produced and on their growth phase .
8-1	1356-1359	The	abstract[68]	new[68]	coref	11-31[118_68]
8-2	1360-1363	EVs	abstract|abstract[68]	giv|new[68]	coref	9-8
8-3	1364-1375	composition	abstract[68]	new[68]	_	_
8-4	1376-1379	and	_	_	_	_
8-5	1380-1387	content	abstract	giv	coref	11-8
8-6	1388-1391	are	_	_	_	_
8-7	1392-1400	strictly	_	_	_	_
8-8	1401-1410	dependent	_	_	_	_
8-9	1411-1413	on	_	_	_	_
8-10	1414-1417	the	abstract[70]	new[70]	ana	8-14[0_70]
8-11	1418-1431	environmental	abstract[70]	new[70]	_	_
8-12	1432-1442	conditions	abstract[70]	new[70]	_	_
8-13	1443-1448	where	_	_	_	_
8-14	1449-1453	they	abstract	giv	ana	8-27
8-15	1454-1457	are	_	_	_	_
8-16	1458-1467	generated	_	_	_	_
8-17	1468-1469	,	_	_	_	_
8-18	1470-1472	as	_	_	_	_
8-19	1473-1477	well	_	_	_	_
8-20	1478-1480	as	_	_	_	_
8-21	1481-1483	on	_	_	_	_
8-22	1484-1487	the	abstract[73]	new[73]	ana	9-61[0_73]
8-23	1488-1497	bacterial	animal|abstract[73]	giv|new[73]	coref	9-56
8-24	1498-1505	species	abstract[73]	new[73]	_	_
8-25	1506-1510	from	_	_	_	_
8-26	1511-1516	which	_	_	_	_
8-27	1517-1521	they	abstract	giv	ana	8-32
8-28	1522-1525	are	_	_	_	_
8-29	1526-1534	produced	_	_	_	_
8-30	1535-1538	and	_	_	_	_
8-31	1539-1541	on	_	_	_	_
8-32	1542-1547	their	abstract|abstract[77]	giv|new[77]	coref|coref	9-4[78_0]|11-14[112_77]
8-33	1548-1554	growth	abstract|abstract[77]	giv|new[77]	coref	11-15
8-34	1555-1560	phase	abstract[77]	new[77]	_	_
8-35	1561-1562	.	_	_	_	_

#Text=For example , iron-limiting conditions increase the EVs production from Helicobacter pylori , Haemophilus influenzae , Escherichia coli , and Vibrio cholera ; the oxygen availability affects the generation of EVs and the antibiotic treatment ( i. e. , polymyxin B or colistin ) promotes an increase of EVs production that confers protection to the bacterial cells , thus allowing their survival .
9-1	1563-1566	For	_	_	_	_
9-2	1567-1574	example	_	_	_	_
9-3	1575-1576	,	_	_	_	_
9-4	1577-1590	iron-limiting	abstract[78]	giv[78]	coref	16-19[198_78]
9-5	1591-1601	conditions	abstract[78]	giv[78]	_	_
9-6	1602-1610	increase	_	_	_	_
9-7	1611-1614	the	abstract[80]	new[80]	coref	9-49[95_80]
9-8	1615-1618	EVs	object|abstract[80]	giv|new[80]	coref	9-31
9-9	1619-1629	production	abstract[80]	new[80]	_	_
9-10	1630-1634	from	abstract[80]	new[80]	_	_
9-11	1635-1647	Helicobacter	abstract[80]|person|substance[82]	new[80]|new|new[82]	coref|coref	12-1|12-2[0_82]
9-12	1648-1654	pylori	abstract[80]|substance[82]	new[80]|new[82]	_	_
9-13	1655-1656	,	abstract[80]	new[80]	_	_
9-14	1657-1668	Haemophilus	abstract[80]|abstract	new[80]|new	_	_
9-15	1669-1679	influenzae	abstract[80]	new[80]	_	_
9-16	1680-1681	,	abstract[80]	new[80]	_	_
9-17	1682-1693	Escherichia	abstract[80]	new[80]	_	_
9-18	1694-1698	coli	abstract[80]	new[80]	_	_
9-19	1699-1700	,	abstract[80]	new[80]	_	_
9-20	1701-1704	and	abstract[80]	new[80]	_	_
9-21	1705-1711	Vibrio	abstract[80]|person|animal[85]	new[80]|new|new[85]	_	_
9-22	1712-1719	cholera	abstract[80]|animal[85]	new[80]|new[85]	_	_
9-23	1720-1721	;	_	_	_	_
9-24	1722-1725	the	abstract[87]	new[87]	_	_
9-25	1726-1732	oxygen	substance|abstract[87]	new|new[87]	_	_
9-26	1733-1745	availability	abstract[87]	new[87]	_	_
9-27	1746-1753	affects	_	_	_	_
9-28	1754-1757	the	event[88]	giv[88]	_	_
9-29	1758-1768	generation	event[88]	giv[88]	_	_
9-30	1769-1771	of	event[88]	giv[88]	_	_
9-31	1772-1775	EVs	event[88]|abstract	giv[88]|giv	coref	9-49
9-32	1776-1779	and	_	_	_	_
9-33	1780-1783	the	abstract[91]	new[91]	coref	10-12[103_91]
9-34	1784-1794	antibiotic	substance|abstract[91]	new|new[91]	_	_
9-35	1795-1804	treatment	abstract[91]	new[91]	_	_
9-36	1805-1806	(	_	_	_	_
9-37	1807-1809	i.	_	_	_	_
9-38	1810-1812	e.	_	_	_	_
9-39	1813-1814	,	_	_	_	_
9-40	1815-1824	polymyxin	_	_	_	_
9-41	1825-1826	B	_	_	_	_
9-42	1827-1829	or	_	_	_	_
9-43	1830-1838	colistin	object	new	_	_
9-44	1839-1840	)	_	_	_	_
9-45	1841-1849	promotes	_	_	_	_
9-46	1850-1852	an	quantity[93]	new[93]	_	_
9-47	1853-1861	increase	quantity[93]	new[93]	_	_
9-48	1862-1864	of	quantity[93]	new[93]	_	_
9-49	1865-1868	EVs	quantity[93]|abstract|abstract[95]	new[93]|giv|giv[95]	coref|coref	10-16[104_95]|10-19
9-50	1869-1879	production	quantity[93]|abstract[95]	new[93]|giv[95]	_	_
9-51	1880-1884	that	_	_	_	_
9-52	1885-1892	confers	_	_	_	_
9-53	1893-1903	protection	abstract	new	_	_
9-54	1904-1906	to	_	_	_	_
9-55	1907-1910	the	object[98]	giv[98]	coref	13-13[151_98]
9-56	1911-1920	bacterial	substance|object[98]	giv|giv[98]	coref	11-23
9-57	1921-1926	cells	object[98]	giv[98]	_	_
9-58	1927-1928	,	_	_	_	_
9-59	1929-1933	thus	_	_	_	_
9-60	1934-1942	allowing	_	_	_	_
9-61	1943-1948	their	abstract|event[100]	giv|new[100]	_	_
9-62	1949-1957	survival	event[100]	new[100]	_	_
9-63	1958-1959	.	_	_	_	_

#Text=A previous study , performed on Stenotrophomonas maltophilia , demonstrated that the imipenem treatment increases the production of EVs delivering β-lactamases .
10-1	1960-1961	A	abstract[101]	new[101]	_	_
10-2	1962-1970	previous	abstract[101]	new[101]	_	_
10-3	1971-1976	study	abstract[101]	new[101]	_	_
10-4	1977-1978	,	_	_	_	_
10-5	1979-1988	performed	_	_	_	_
10-6	1989-1991	on	_	_	_	_
10-7	1992-2008	Stenotrophomonas	_	_	_	_
10-8	2009-2020	maltophilia	_	_	_	_
10-9	2021-2022	,	_	_	_	_
10-10	2023-2035	demonstrated	_	_	_	_
10-11	2036-2040	that	_	_	_	_
10-12	2041-2044	the	abstract[103]	giv[103]	_	_
10-13	2045-2053	imipenem	abstract|abstract[103]	new|giv[103]	_	_
10-14	2054-2063	treatment	abstract[103]	giv[103]	_	_
10-15	2064-2073	increases	_	_	_	_
10-16	2074-2077	the	abstract[104]	giv[104]	_	_
10-17	2078-2088	production	abstract[104]	giv[104]	_	_
10-18	2089-2091	of	abstract[104]	giv[104]	_	_
10-19	2092-2095	EVs	abstract[104]|abstract	giv[104]|giv	coref	11-5
10-20	2096-2106	delivering	_	_	_	_
10-21	2107-2119	β-lactamases	substance	new	_	_
10-22	2120-2121	.	_	_	_	_

#Text=Modifications in terms of EVs production and content might also be associated with the growth phase , as well as with the bacterial phenotype ( biofilm or planktonic ) and the media composition . Park et al. demonstrated that EVs associated to the P. aeruginosa biofilm phenotype showed a unique proteome profile , with respect to the one carried by EVs stemming from its planktonic counterpart .
11-1	2122-2135	Modifications	abstract[107]	new[107]	coref	16-13[195_107]
11-2	2136-2138	in	abstract[107]	new[107]	_	_
11-3	2139-2144	terms	abstract[107]	new[107]	_	_
11-4	2145-2147	of	abstract[107]	new[107]	_	_
11-5	2148-2151	EVs	abstract[107]|abstract|abstract[109]	new[107]|giv|new[109]	coref|coref	11-40|16-16[197_109]
11-6	2152-2162	production	abstract[107]|abstract[109]	new[107]|new[109]	_	_
11-7	2163-2166	and	abstract[107]	new[107]	_	_
11-8	2167-2174	content	abstract[107]|abstract	new[107]|giv	_	_
11-9	2175-2180	might	_	_	_	_
11-10	2181-2185	also	_	_	_	_
11-11	2186-2188	be	_	_	_	_
11-12	2189-2199	associated	_	_	_	_
11-13	2200-2204	with	_	_	_	_
11-14	2205-2208	the	abstract[112]	giv[112]	_	_
11-15	2209-2215	growth	abstract|abstract[112]	giv|giv[112]	_	_
11-16	2216-2221	phase	abstract[112]	giv[112]	_	_
11-17	2222-2223	,	_	_	_	_
11-18	2224-2226	as	_	_	_	_
11-19	2227-2231	well	_	_	_	_
11-20	2232-2234	as	_	_	_	_
11-21	2235-2239	with	_	_	_	_
11-22	2240-2243	the	quantity[114]	new[114]	coref	11-43[122_114]
11-23	2244-2253	bacterial	substance|quantity[114]	giv|new[114]	coref	13-13
11-24	2254-2263	phenotype	quantity[114]	new[114]	_	_
11-25	2264-2265	(	_	_	_	_
11-26	2266-2273	biofilm	substance	giv	coref	11-46
11-27	2274-2276	or	_	_	_	_
11-28	2277-2287	planktonic	abstract	new	coref	12-15[139_0]
11-29	2288-2289	)	_	_	_	_
11-30	2290-2293	and	_	_	_	_
11-31	2294-2297	the	abstract[118]	giv[118]	_	_
11-32	2298-2303	media	abstract|abstract[118]	new|giv[118]	_	_
11-33	2304-2315	composition	abstract[118]	giv[118]	_	_
11-34	2316-2317	.	_	_	_	_
11-35	2318-2322	Park	person	new	_	_
11-36	2323-2325	et	_	_	_	_
11-37	2326-2329	al.	_	_	_	_
11-38	2330-2342	demonstrated	_	_	_	_
11-39	2343-2347	that	_	_	_	_
11-40	2348-2351	EVs	abstract	giv	coref	11-61
11-41	2352-2362	associated	_	_	_	_
11-42	2363-2365	to	_	_	_	_
11-43	2366-2369	the	quantity[122]	giv[122]	coref	14-9[164_122]
11-44	2370-2372	P.	quantity[122]	giv[122]	_	_
11-45	2373-2383	aeruginosa	quantity[122]	giv[122]	_	_
11-46	2384-2391	biofilm	object|quantity[122]	giv|giv[122]	ana	11-64
11-47	2392-2401	phenotype	quantity[122]	giv[122]	_	_
11-48	2402-2408	showed	_	_	_	_
11-49	2409-2410	a	abstract[124]	new[124]	_	_
11-50	2411-2417	unique	abstract[124]	new[124]	_	_
11-51	2418-2426	proteome	abstract|abstract[124]	new|new[124]	_	_
11-52	2427-2434	profile	abstract[124]	new[124]	_	_
11-53	2435-2436	,	_	_	_	_
11-54	2437-2441	with	_	_	_	_
11-55	2442-2449	respect	abstract[125]	new[125]	_	_
11-56	2450-2452	to	abstract[125]	new[125]	_	_
11-57	2453-2456	the	abstract[125]|abstract[126]	new[125]|new[126]	_	_
11-58	2457-2460	one	abstract[125]|abstract[126]	new[125]|new[126]	_	_
11-59	2461-2468	carried	_	_	_	_
11-60	2469-2471	by	_	_	_	_
11-61	2472-2475	EVs	abstract	giv	coref	12-23
11-62	2476-2484	stemming	_	_	_	_
11-63	2485-2489	from	_	_	_	_
11-64	2490-2493	its	substance|object[129]	giv|new[129]	coref	12-20
11-65	2494-2504	planktonic	object[129]	new[129]	_	_
11-66	2505-2516	counterpart	object[129]	new[129]	_	_
11-67	2517-2518	.	_	_	_	_

#Text=Helicobacter pylori ATCC 43629 and Lactobacillus reuteri DSM 17938 are biofilm-producing strains , and both the planktonic and the biofilm phenotypes generate EVs ( pEVs and bEVs , respectively ) carrying extracellular DNA ( eDNA). .
12-1	2519-2531	Helicobacter	person	giv	_	_
12-2	2532-2538	pylori	substance|abstract[132]	giv|new[132]	_	_
12-3	2539-2543	ATCC	abstract[132]	new[132]	_	_
12-4	2544-2549	43629	quantity	new	coref	15-59
12-5	2550-2553	and	_	_	_	_
12-6	2554-2567	Lactobacillus	abstract|person[135]	new|new[135]	_	_
12-7	2568-2575	reuteri	person[135]	new[135]	_	_
12-8	2576-2579	DSM	person[135]|abstract|abstract[137]	new[135]|new|new[137]	coref	15-67[191_0]
12-9	2580-2585	17938	person[135]|abstract[137]	new[135]|new[137]	_	_
12-10	2586-2589	are	_	_	_	_
12-11	2590-2607	biofilm-producing	_	_	_	_
12-12	2608-2615	strains	abstract	new	_	_
12-13	2616-2617	,	_	_	_	_
12-14	2618-2621	and	_	_	_	_
12-15	2622-2626	both	abstract[139]	giv[139]	coref	15-46[184_139]
12-16	2627-2630	the	abstract[139]	giv[139]	_	_
12-17	2631-2641	planktonic	abstract[139]	giv[139]	_	_
12-18	2642-2645	and	_	_	_	_
12-19	2646-2649	the	abstract[141]	new[141]	coref	15-49[186_141]
12-20	2650-2657	biofilm	object|abstract[141]	giv|new[141]	coref	13-48[160_0]
12-21	2658-2668	phenotypes	abstract[141]	new[141]	_	_
12-22	2669-2677	generate	_	_	_	_
12-23	2678-2681	EVs	abstract	giv	appos	12-25[144_0]
12-24	2682-2683	(	_	_	_	_
12-25	2684-2688	pEVs	object|abstract[144]	new|giv[144]	coref	13-32[0_144]
12-26	2689-2692	and	abstract[144]	giv[144]	_	_
12-27	2693-2697	bEVs	abstract[144]|person[145]	giv[144]|new[145]	_	_
12-28	2698-2699	,	abstract[144]|person[145]	giv[144]|new[145]	_	_
12-29	2700-2712	respectively	abstract[144]|person[145]	giv[144]|new[145]	_	_
12-30	2713-2714	)	_	_	_	_
12-31	2715-2723	carrying	_	_	_	_
12-32	2724-2737	extracellular	abstract[146]	new[146]	appos	12-35[0_146]
12-33	2738-2741	DNA	abstract[146]	new[146]	_	_
12-34	2742-2743	(	_	_	_	_
12-35	2744-2750	eDNA).	abstract	giv	_	_
12-36	2751-2752	.	_	_	_	_

#Text=In particular , H. pylori -derived bEVs seemed to “ bridge ” bacterial cells , thus playing a possible structural role ; however , the fact that eDNA are carried by EVs , may protect the eDNA from the enzymatic activity of DNase I in breaking up the biofilm .
13-1	2753-2755	In	_	_	_	_
13-2	2756-2766	particular	_	_	_	_
13-3	2767-2768	,	_	_	_	_
13-4	2769-2771	H.	person[148]	new[148]	coref	15-56[188_148]
13-5	2772-2778	pylori	person[148]	new[148]	_	_
13-6	2779-2787	-derived	_	_	_	_
13-7	2788-2792	bEVs	person	new	_	_
13-8	2793-2799	seemed	_	_	_	_
13-9	2800-2802	to	_	_	_	_
13-10	2803-2804	“	_	_	_	_
13-11	2805-2811	bridge	_	_	_	_
13-12	2812-2813	”	_	_	_	_
13-13	2814-2823	bacterial	substance|object[151]	giv|giv[151]	coref	15-29
13-14	2824-2829	cells	object[151]	giv[151]	_	_
13-15	2830-2831	,	_	_	_	_
13-16	2832-2836	thus	_	_	_	_
13-17	2837-2844	playing	_	_	_	_
13-18	2845-2846	a	abstract[152]	new[152]	_	_
13-19	2847-2855	possible	abstract[152]	new[152]	_	_
13-20	2856-2866	structural	abstract[152]	new[152]	_	_
13-21	2867-2871	role	abstract[152]	new[152]	_	_
13-22	2872-2873	;	_	_	_	_
13-23	2874-2881	however	abstract[153]	new[153]	_	_
13-24	2882-2883	,	abstract[153]	new[153]	_	_
13-25	2884-2887	the	abstract[153]	new[153]	_	_
13-26	2888-2892	fact	abstract[153]	new[153]	_	_
13-27	2893-2897	that	abstract[153]	new[153]	_	_
13-28	2898-2902	eDNA	abstract[153]|substance	new[153]|new	coref	13-36[156_0]
13-29	2903-2906	are	abstract[153]	new[153]	_	_
13-30	2907-2914	carried	abstract[153]	new[153]	_	_
13-31	2915-2917	by	abstract[153]	new[153]	_	_
13-32	2918-2921	EVs	abstract[153]|substance	new[153]|giv	coref	14-6
13-33	2922-2923	,	abstract[153]	new[153]	_	_
13-34	2924-2927	may	abstract[153]	new[153]	_	_
13-35	2928-2935	protect	abstract[153]	new[153]	_	_
13-36	2936-2939	the	abstract[153]|substance[156]	new[153]|giv[156]	coref	14-17[0_156]
13-37	2940-2944	eDNA	abstract[153]|substance[156]	new[153]|giv[156]	_	_
13-38	2945-2949	from	_	_	_	_
13-39	2950-2953	the	abstract[157]	new[157]	_	_
13-40	2954-2963	enzymatic	abstract[157]	new[157]	_	_
13-41	2964-2972	activity	abstract[157]	new[157]	_	_
13-42	2973-2975	of	abstract[157]	new[157]	_	_
13-43	2976-2981	DNase	abstract[157]|abstract	new[157]|new	ana	14-1
13-44	2982-2983	I	person	acc	_	_
13-45	2984-2986	in	_	_	_	_
13-46	2987-2995	breaking	_	_	_	_
13-47	2996-2998	up	_	_	_	_
13-48	2999-3002	the	substance[160]	giv[160]	coref	14-10[0_160]
13-49	3003-3010	biofilm	substance[160]	giv[160]	_	_
13-50	3011-3012	.	_	_	_	_

#Text=It cannot be dismissed that EVs produced from the biofilm phenotype may represent a shuttle for eDNA transport .
14-1	3013-3015	It	abstract	giv	_	_
14-2	3016-3022	cannot	_	_	_	_
14-3	3023-3025	be	_	_	_	_
14-4	3026-3035	dismissed	_	_	_	_
14-5	3036-3040	that	_	_	_	_
14-6	3041-3044	EVs	abstract	giv	coref	15-31
14-7	3045-3053	produced	_	_	_	_
14-8	3054-3058	from	_	_	_	_
14-9	3059-3062	the	quantity[164]	giv[164]	_	_
14-10	3063-3070	biofilm	substance|quantity[164]	giv|giv[164]	coref	15-50
14-11	3071-3080	phenotype	quantity[164]	giv[164]	_	_
14-12	3081-3084	may	_	_	_	_
14-13	3085-3094	represent	_	_	_	_
14-14	3095-3096	a	abstract[165]	new[165]	_	_
14-15	3097-3104	shuttle	abstract[165]	new[165]	_	_
14-16	3105-3108	for	abstract[165]	new[165]	_	_
14-17	3109-3113	eDNA	abstract[165]|abstract|abstract[167]	new[165]|giv|new[167]	_	_
14-18	3114-3123	transport	abstract[165]|abstract[167]	new[165]|new[167]	_	_
14-19	3124-3125	.	_	_	_	_

#Text=For all of these reasons , we aimed to optimize a simplified Polychromatic Flow Cytometry ( PFC ) method for a fast identification , enumeration and characterization of bacterial derived EVs , as well as for the analysis of their eDNA-associated subtypes , produced by the planktonic and the biofilm phenotypes of a Gram-negative ( H. pylori ATCC 43629 ) and a Gram-positive ( L. reuteri DSM 17938 ) bacterium .
15-1	3126-3129	For	_	_	_	_
15-2	3130-3133	all	abstract[168]	new[168]	_	_
15-3	3134-3136	of	abstract[168]	new[168]	_	_
15-4	3137-3142	these	abstract[168]	new[168]	_	_
15-5	3143-3150	reasons	abstract[168]	new[168]	_	_
15-6	3151-3152	,	_	_	_	_
15-7	3153-3155	we	person	acc	ana	16-1
15-8	3156-3161	aimed	_	_	_	_
15-9	3162-3164	to	_	_	_	_
15-10	3165-3173	optimize	_	_	_	_
15-11	3174-3175	a	abstract[172]|abstract[174]	new[172]|new[174]	appos	15-17[0_172]
15-12	3176-3186	simplified	abstract[172]|abstract[174]	new[172]|new[174]	_	_
15-13	3187-3200	Polychromatic	abstract|abstract[172]|abstract[174]	new|new[172]|new[174]	_	_
15-14	3201-3205	Flow	abstract|abstract[172]|abstract[174]	new|new[172]|new[174]	_	_
15-15	3206-3215	Cytometry	abstract[172]|abstract[174]	new[172]|new[174]	_	_
15-16	3216-3217	(	abstract[174]	new[174]	_	_
15-17	3218-3221	PFC	abstract|abstract[174]	giv|new[174]	coref	16-4
15-18	3222-3223	)	abstract[174]	new[174]	_	_
15-19	3224-3230	method	abstract[174]	new[174]	_	_
15-20	3231-3234	for	abstract[174]	new[174]	_	_
15-21	3235-3236	a	abstract[174]|abstract[175]|abstract[176]	new[174]|new[175]|new[176]	ana	15-40[0_176]
15-22	3237-3241	fast	abstract[174]|abstract[175]|abstract[176]	new[174]|new[175]|new[176]	_	_
15-23	3242-3256	identification	abstract[174]|abstract[175]|abstract[176]	new[174]|new[175]|new[176]	_	_
15-24	3257-3258	,	abstract[174]|abstract[176]	new[174]|new[176]	_	_
15-25	3259-3270	enumeration	abstract[174]|abstract[176]|abstract	new[174]|new[176]|new	coref	16-30[200_0]
15-26	3271-3274	and	abstract[174]|abstract[176]	new[174]|new[176]	_	_
15-27	3275-3291	characterization	abstract[174]|abstract[176]|abstract[178]	new[174]|new[176]|new[178]	_	_
15-28	3292-3294	of	abstract[174]|abstract[176]|abstract[178]	new[174]|new[176]|new[178]	_	_
15-29	3295-3304	bacterial	abstract[174]|abstract[176]|abstract[178]|substance	new[174]|new[176]|new[178]|giv	coref	16-32
15-30	3305-3312	derived	_	_	_	_
15-31	3313-3316	EVs	object	giv	coref	16-16
15-32	3317-3318	,	_	_	_	_
15-33	3319-3321	as	_	_	_	_
15-34	3322-3326	well	_	_	_	_
15-35	3327-3329	as	_	_	_	_
15-36	3330-3333	for	_	_	_	_
15-37	3334-3337	the	abstract[181]	new[181]	_	_
15-38	3338-3346	analysis	abstract[181]	new[181]	_	_
15-39	3347-3349	of	abstract[181]	new[181]	_	_
15-40	3350-3355	their	abstract[181]|abstract|abstract[183]	new[181]|giv|new[183]	_	_
15-41	3356-3371	eDNA-associated	abstract[181]|abstract[183]	new[181]|new[183]	_	_
15-42	3372-3380	subtypes	abstract[181]|abstract[183]	new[181]|new[183]	_	_
15-43	3381-3382	,	_	_	_	_
15-44	3383-3391	produced	_	_	_	_
15-45	3392-3394	by	_	_	_	_
15-46	3395-3398	the	abstract[184]	giv[184]	_	_
15-47	3399-3409	planktonic	abstract[184]	giv[184]	_	_
15-48	3410-3413	and	_	_	_	_
15-49	3414-3417	the	abstract[186]	giv[186]	_	_
15-50	3418-3425	biofilm	substance|abstract[186]	giv|giv[186]	_	_
15-51	3426-3436	phenotypes	abstract[186]	giv[186]	_	_
15-52	3437-3439	of	abstract[186]	giv[186]	_	_
15-53	3440-3441	a	abstract[186]|substance[187]	giv[186]|giv[187]	_	_
15-54	3442-3455	Gram-negative	abstract[186]|substance[187]	giv[186]|giv[187]	_	_
15-55	3456-3457	(	_	_	_	_
15-56	3458-3460	H.	person[188]	giv[188]	_	_
15-57	3461-3467	pylori	person[188]	giv[188]	_	_
15-58	3468-3472	ATCC	person[188]	giv[188]	_	_
15-59	3473-3478	43629	person[188]|quantity	giv[188]|giv	_	_
15-60	3479-3480	)	_	_	_	_
15-61	3481-3484	and	_	_	_	_
15-62	3485-3486	a	substance[190]	new[190]	_	_
15-63	3487-3500	Gram-positive	substance[190]	new[190]	_	_
15-64	3501-3502	(	substance[190]	new[190]	_	_
15-65	3503-3505	L.	substance[190]	new[190]	_	_
15-66	3506-3513	reuteri	substance[190]	new[190]	_	_
15-67	3514-3517	DSM	substance[190]|abstract[191]	new[190]|giv[191]	_	_
15-68	3518-3523	17938	substance[190]|abstract[191]	new[190]|giv[191]	_	_
15-69	3524-3525	)	substance[190]	new[190]	_	_
15-70	3526-3535	bacterium	substance[190]|animal	new[190]|giv	_	_
15-71	3536-3537	.	_	_	_	_

#Text=We demonstrated that PFC can be used as a tool to study the modifications of EVs production under different environmental conditions , as well as for the detection and enumeration of bacterial derived EVs , and in particular eDNA-associated EVs , in clinical samples .
16-1	3538-3540	We	person	giv	_	_
16-2	3541-3553	demonstrated	_	_	_	_
16-3	3554-3558	that	_	_	_	_
16-4	3559-3562	PFC	object	giv	_	_
16-5	3563-3566	can	_	_	_	_
16-6	3567-3569	be	_	_	_	_
16-7	3570-3574	used	_	_	_	_
16-8	3575-3577	as	_	_	_	_
16-9	3578-3579	a	_	_	_	_
16-10	3580-3584	tool	_	_	_	_
16-11	3585-3587	to	_	_	_	_
16-12	3588-3593	study	_	_	_	_
16-13	3594-3597	the	abstract[195]	giv[195]	_	_
16-14	3598-3611	modifications	abstract[195]	giv[195]	_	_
16-15	3612-3614	of	abstract[195]	giv[195]	_	_
16-16	3615-3618	EVs	abstract[195]|abstract|abstract[197]	giv[195]|giv|giv[197]	coref	16-34
16-17	3619-3629	production	abstract[195]|abstract[197]	giv[195]|giv[197]	_	_
16-18	3630-3635	under	abstract[195]|abstract[197]	giv[195]|giv[197]	_	_
16-19	3636-3645	different	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
16-20	3646-3659	environmental	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
16-21	3660-3670	conditions	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
16-22	3671-3672	,	abstract[195]	giv[195]	_	_
16-23	3673-3675	as	abstract[195]	giv[195]	_	_
16-24	3676-3680	well	abstract[195]	giv[195]	_	_
16-25	3681-3683	as	abstract[195]	giv[195]	_	_
16-26	3684-3687	for	abstract[195]	giv[195]	_	_
16-27	3688-3691	the	abstract[195]|abstract[199]	giv[195]|new[199]	_	_
16-28	3692-3701	detection	abstract[195]|abstract[199]	giv[195]|new[199]	_	_
16-29	3702-3705	and	abstract[195]	giv[195]	_	_
16-30	3706-3717	enumeration	abstract[195]|abstract[200]	giv[195]|giv[200]	_	_
16-31	3718-3720	of	abstract[195]|abstract[200]	giv[195]|giv[200]	_	_
16-32	3721-3730	bacterial	abstract[195]|abstract[200]|substance	giv[195]|giv[200]|giv	_	_
16-33	3731-3738	derived	abstract[195]	giv[195]	_	_
16-34	3739-3742	EVs	abstract[195]|object	giv[195]|giv	coref	16-38[203_0]
16-35	3743-3744	,	abstract[195]	giv[195]	_	_
16-36	3745-3748	and	abstract[195]	giv[195]	_	_
16-37	3749-3751	in	abstract[195]	giv[195]	_	_
16-38	3752-3762	particular	abstract[195]|abstract[203]	giv[195]|giv[203]	_	_
16-39	3763-3778	eDNA-associated	abstract[195]|abstract[203]	giv[195]|giv[203]	_	_
16-40	3779-3782	EVs	abstract[195]|abstract[203]	giv[195]|giv[203]	_	_
16-41	3783-3784	,	abstract[195]|abstract[203]	giv[195]|giv[203]	_	_
16-42	3785-3787	in	abstract[195]|abstract[203]	giv[195]|giv[203]	_	_
16-43	3788-3796	clinical	abstract[195]|abstract[203]|object[204]	giv[195]|giv[203]|new[204]	_	_
16-44	3797-3804	samples	abstract[195]|abstract[203]|object[204]	giv[195]|giv[203]|new[204]	_	_
16-45	3805-3806	.	_	_	_	_
